AXDX vs. HLTH, TLIS, OMIC, TBIO, PRPO, RPID, BNGO, AIM, EKSO, and VINC
Should you be buying Accelerate Diagnostics stock or one of its competitors? The main competitors of Accelerate Diagnostics include Cue Health (HLTH), Talis Biomedical (TLIS), Singular Genomics Systems (OMIC), Telesis Bio (TBIO), Precipio (PRPO), Rapid Micro Biosystems (RPID), Bionano Genomics (BNGO), AIM ImmunoTech (AIM), Ekso Bionics (EKSO), and Vincerx Pharma (VINC). These companies are all part of the "medical" sector.
Accelerate Diagnostics (NASDAQ:AXDX) and Cue Health (NASDAQ:HLTH) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, dividends, community ranking, valuation, profitability, risk, earnings, institutional ownership and media sentiment.
Accelerate Diagnostics has a beta of 0.52, suggesting that its stock price is 48% less volatile than the S&P 500. Comparatively, Cue Health has a beta of 1.23, suggesting that its stock price is 23% more volatile than the S&P 500.
Accelerate Diagnostics has higher earnings, but lower revenue than Cue Health. Accelerate Diagnostics is trading at a lower price-to-earnings ratio than Cue Health, indicating that it is currently the more affordable of the two stocks.
In the previous week, Accelerate Diagnostics had 4 more articles in the media than Cue Health. MarketBeat recorded 4 mentions for Accelerate Diagnostics and 0 mentions for Cue Health. Accelerate Diagnostics' average media sentiment score of 0.08 beat Cue Health's score of 0.00 indicating that Accelerate Diagnostics is being referred to more favorably in the media.
Accelerate Diagnostics presently has a consensus price target of $1.00, indicating a potential upside of 7.52%. Cue Health has a consensus price target of $3.00, indicating a potential upside of 2,027.66%. Given Cue Health's higher possible upside, analysts clearly believe Cue Health is more favorable than Accelerate Diagnostics.
17.1% of Accelerate Diagnostics shares are owned by institutional investors. Comparatively, 45.5% of Cue Health shares are owned by institutional investors. 43.6% of Accelerate Diagnostics shares are owned by insiders. Comparatively, 12.5% of Cue Health shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Accelerate Diagnostics has a net margin of -454.95% compared to Cue Health's net margin of -526.48%. Accelerate Diagnostics' return on equity of 0.00% beat Cue Health's return on equity.
Accelerate Diagnostics received 353 more outperform votes than Cue Health when rated by MarketBeat users. Likewise, 63.55% of users gave Accelerate Diagnostics an outperform vote while only 7.14% of users gave Cue Health an outperform vote.
Summary
Accelerate Diagnostics beats Cue Health on 11 of the 18 factors compared between the two stocks.
Get Accelerate Diagnostics News Delivered to You Automatically
Sign up to receive the latest news and ratings for AXDX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AXDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Accelerate Diagnostics Competitors List
Related Companies and Tools
